Targeted drugs represented by epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) have shown great benefits in EGFR-mutated non-small-cell lung cancer (NSCLC) in recent years (3, 4). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.